AlFx affects the formation of focal complexes by stabilizing the Arf-GAP ASAP1 in a complex with Arf1  by Klein, Stéphanie et al.
FEBS 30044 FEBS Letters 579 (2005) 5741–5745AlFx aﬀects the formation of focal complexes by stabilizing
the Arf-GAP ASAP1 in a complex with Arf1
Ste´phanie Klein, Michel Franco, Pierre Chardin, Fre´de´ric Luton*
Institut de Pharmacologie Mole´culaire et Cellulaire, CNRS-UMR 6097, 660 route des Lucioles, 06560 Valbonne, France
Received 1 August 2005; revised 8 September 2005; accepted 22 September 2005
Available online 5 October 2005
Edited by Felix WielandAbstract Aluminum ﬂuoride (AlFx) is known to activate di-
rectly the a subunit of G-proteins but not the homologous small
GTP-binding proteins. However, AlFx can stabilize complexes
formed between Ras, RhoA or Cdc42 and their corresponding
GTPase-activating proteins (GAPs). Here, we demonstrate that
Arf1GDP can be converted into an active conformation by AlFx
to form a complex with the Arf-GAP ASAP1 in vitro and in vivo.
Within this complex ASAP1, which GAP activity is inoperative,
can still alter the recruitment of paxillin to the focal complexes,
thus indicating that ASAP1 interferes with focal complexes inde-
pendently of its GAP activity.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The ADP-ribosylation factor (Arf) family of small GTP-
binding proteins comprise six members among which Arf1
and Arf6 are the most extensively studied. Arf1 functions in
ER-to-Golgi and intra-Golgi vesicular transport by recruiting
the COPI coat onto Golgi membranes, while Arf6 is involved
in peripheral membrane traﬃcking and actin cytoskeleton
organization [1]. Because of their very low intrinsic nucleotide
exchange and GTPase activities, Arf proteins are regulated by
guanine exchange factors (GEFs) and GTPase-activating pro-
teins (GAPs), respectively.
The Arf-GAP family includes at least 15 members charac-
terized by a conserved zinc ﬁnger motif within the catalytic
domain. They are multidomain proteins that can be catego-
rized based on their structural domain organization [2].
ASAP1 is a PIP2-dependent Arf-GAP that has been proposed
to coordinate membrane traﬃcking with actin remodeling. It
has been found to bind to the non-receptor tyrosine kinases
p60src and focal adhesion kinase (FAK) and, more recently,
to the adaptor protein CD2-associated protein (CD2AP) [3–
5]. In vitro assays indicate that ASAP1 is more active on
Arf1 and Arf5 than on Arf6 [3]. Further, a cell-based GAPAbbreviations: AlFx, aluminum ﬂuoride; Arf, ADP-ribosylation fac-
tor; FC, focal complex; GAP, GTPase-activating protein
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but not Arf6 [6]. In various ﬁbroblastic cell lines ASAP1 is
a cytosolic protein with a small fraction detected at the mem-
brane periphery where it colocalizes with focal adhesions (lo-
cated underneath the cell body) and focal complexes (FCs,
located at the cell periphery) markers such as paxillin, b1-inte-
grin and FAK. At the immunoﬂuorescence microscopic level,
ASAP1 seems to be absent from and not to disrupt the Golgi
apparatus and the endocytic compartments [7]. Noteworthy,
exogenous expression of ASAP1 was shown to interfere with
FCs formation, cell spreading, PDGF-induced ruﬄing and
cell migration. The use of a catalytic point mutant (R497K)
suggested that the observed eﬀects were dependent upon the
Arf-GAP activity [4,5,7]. In contrast, expression of the pro-
tein ASAP1 deleted of the GAP domain suggested that the
GAP activity was required to interfere with cell migration
but not with cell spreading nor the formation of the periphe-
ral FCs [6].
The molecular mechanism by which GAPs stimulate GTP
hydrolysis has been modeled with the large heterotrimeric G-
proteins by using aluminum ﬂuoride (AlFx). The exact nature
of the active species (AlF3 or AlF4) of aluminoﬂuoride com-
plexes is still being investigated [8], therefore we will use the
term AlFx. It was shown that addition of AlFx could activate
the GDP-bound a subunit of heterotrimeric G-protein, and
trigger the conversion to the GTP-bound conformation. AlFx
mimics the terminal c-phosphate of the GTP and is positioned
within the nucleotide pocket of the complex in a conformation
that resembles that of a transition state. A conserved arginine
residue within the catalytic pocket is required to stabilize the
AlFx bound to the Ga-GDP [9]. However, for the small
GTP-binding proteins, experiments revealed that AlFx was
ineﬃcient in directly stimulating the conversion to the GTP-
bound conformation [10]. Structural studies demonstrated that
the required arginine residue was absent from the nucleotide
pocket of the small GTP-binding proteins. However, all the
GAPs for small GTP-binding proteins possess an invariant
arginine residue. It was therefore proposed that the GAP
might be able to stabilize AlFx in the nucleotide pocket of
the small GTP-binding protein forming a trimolecular com-
plex [11]. Biochemical experiments demonstrated that AlFx
stabilized a complex, most likely a transition-state, between
Ras and two corresponding Ras-GAPs. This was later con-
ﬁrmed when the structures of the co-crystals of Ras-GDP-
AlFx with p120GAP and RhoA-GDP-AlFx with p50RhoGAP
were solved [12,13]. Within this complex the GAP activity is
inoperative but the GAP can still act as an eﬀector bound to
the active conformation of its cognate small G protein.ation of European Biochemical Societies.
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the COPI coatomer onto a preparation of Golgi membranes
was shown to be enhanced in the presence of AlFx [14,15].
Similarly, AlFx was shown to induce the formation of large
peripheral membrane protrusions only in cells expressing exog-
enous Arf6 but not in untransfected cells [16,17]. However, be-
cause AlFx had no direct eﬀect on several small G proteins
tested [10], including Arf, it was concluded that the eﬀects of
AlFx accounted for the involvement of heterotrimeric G pro-
teins. Here, we demonstrate that AlFx can stabilize in vitro
and in vivo a complex between Arf1 and ASAP1, and that
in vivo the complex Arf1-AlFx-ASAP1, in which the GAP
activity is ineﬀective, delays the recruitment of paxillin to
FCs. Our results support the role of ASAP1 as an Arf1 eﬀector
altering the formation of FCs and cell spreading which is inde-
pendent of its GAP activity.Fig. 1. Myr-Arf1 forms a stable complex with the PZA fragment of
ASAP1 in the presence of AlFx in vitro. The puriﬁed myristoylated
Arf1 protein loaded with GDP and/or the puriﬁed PZA fragment were
incubated in the absence or presence of AlFx and PIP2-enriched
liposomes for 15 min at 25 C. Following centrifugation the percent-
ages of Arf1 (p-Arf1) and PZA (p-PZA) bound to the vesicles were
quantiﬁed after SDS–PAGE and sypro staining by densitometric
analysis. The results are representative of three independent experi-
ments.2. Materials and methods
2.1. Production and puriﬁcation of recombinant Arf proteins
For the production of myristoylated Arf1 BL21 (DE3) bacteria were
co-transformed with pET-3c-Arf and pBB131 coding for the yeast N-
myristoyl-transferase [18], and puriﬁed as previously described [19].
2.2. Preparation of phospholipid vesicles
Sucrose-loaded liposomes of deﬁned composition were prepared by
extrusion through a 0.4 lm pore polycarbonate ﬁlter Isopore (Millli-
pore, Molsheim, France) [20]. The composition was 50% egg phospha-
tidylcholine, 19% liver phosphatidylethanolamine, 5% brain
phosphatidylserine, 7.5% liver phosphatidylinositol, 16% cholesterol
and 2.5% phosphatidylinositol biphosphate. Lipids were from Avanti
Polar Lipids (Birmingham, AL).
2.3. Sedimentation assay
Myr-Arf1 was loaded with GDP ± AlFx (10 mM NaF and 100 lM
AlCl3) for 30 min at 37 C in the absence or presence of liposomes
(2 mg/ml). When indicated PZA was added and incubated 15 min at
25 C. Liposomes were then separated by ultracentrifugation and the
amount of proteins bound to liposomes was quantiﬁed after SDS–
PAGE and sypro orange (Bio-Rad, France) staining by densitometric
analysis (LAS 3000, Fujiﬁlm, France).
2.4. Transfection, immunoprecipitation and immunoblot
BHK cells grown in 10-cm petri dishes were transfected with the
indicated plasmids using Fugene 6 according to the manufacturers
instructions (Roche Diagnostics, Mannheim, Germany). 24h post-
transfection the cells were exposed or not to AlFx (10 mM NaF and
100 lM AlCl3) for 30 min at 37 C, lyzed in 0.5% Triton X-100,
20 mM HEPES, 125 mM NaCl, 1 mM MgCl2, 1 mM GDP, 0.5 mM
DTSSP (3,3 0-dithiobis[sulfosuccinimidylpropionate]) (Pierce, Perbio
Science, France) and proteases inhibitors (Complete cocktail tablets,
Roche Diagnostics). When indicated the lysis buﬀer was supplemented
with 10 mM NaF and 100 lM AlCl3. Lysates were centrifuged, pre-
cleared and incubated overnight at 4 C with anti-FLAG agarose
beads (Sigma–Aldrich). The immunoprecipitates were washed ﬁve
times, resolved by SDS–PAGE and the indicated proteins detected
after immunoblot by chemiluminescence (ECL, Amersham France).
Mouse monoclonal anti-FLAG M2 and anti-HA (clone 12CA5) anti-
bodies were from Sigma–Aldrich and Roche Diagnostics, respectively.
2.5. Cell-substratum assay and immunoﬂuorescence
REF52 cells were cultured in DMEM supplemented with 10% fetal
bovine serum, 10 lg/ml penicillin and 0.25 lg/ml streptomycin. To fol-
low the formation of FCs, 16 h after transient transfection with full-
length FLAG-ASAP1 construct using Fugene 6 (Roche Diagnostics),
the cells were trypsinized and replated on ﬁbronectin-coated coverslips
(2.5 lg/cm2) for diﬀerent periods of time. When indicated the cells were
exposed to AlFx at 37 C during the last 2 h of the incubation periodby addition of 30 mM NaF and 50 lM AlCl3. At the end of the incu-
bation, the cells were ﬁxed in 4% PFA and processed for immunoﬂu-
orescence analysis as described previously [21]. Polymerized actin,
FCs or ASAP1 were labeled with phalloidin (Sigma–Aldrich), anti-
paxillin (Becton–Dickinson Transduction Laboratories) and anti-
FLAG antibodies (Sigma–Aldrich), respectively. Confocal microscopy
analysis was carried out with a Leica TCS-SP microscope equipped
with a mixed-gas argon/krypton laser (Leica Microsystems).3. Results
To determine if AlFx can stabilize the formation of a com-
plex between Arf1 and ASAP1 we performed a sedimentation
assay using puriﬁed proteins and lipid vesicles. This assay is
based on the biochemical properties of Arf1, which is soluble
in its inactive GDP-bound form and lipid membrane-associ-
ated in its active GTP-bound form [22,23]. Thus, when the
myristoylated Arf1 (myr-Arf1) loaded with GDP or the PZA
fragment, the minimal active fragment of the Arf1-GAP
ASAP1 [3], were incubated with liposomes they were found
to be mostly soluble (Fig. 1). Only 27% of myr-Arf1 and
34% of PZA were recovered in the pelleted membrane fraction.
The addition of AlFx did not change the sedimentation prop-
erties of either protein. However, when mixed together in the
presence of AlFx, both PZA and myr-Arf1 translocated into
the pellet within the same proportions 74% and 83%, respec-
tively (Fig. 1). These results illustrate directly for the ﬁrst time
the formation of a complex between the activated form of Arf1
(Arf1GDP-AlFx) and an Arf-GAP. Taking into account that
680 nM (34% of 2 lM) of PZA spontaneously associated with
the liposomes, 800 nM of PZA (74% of 2 lM minus 680 nM)
was recruited by approximately 830 nM of myr-Arf1GDP-
AlFx (83% of 1 lM) assuming that the majority of the mem-
brane-bound Myr-Arf1GDP (27%) had been converted to
an active conformation. Thus, the quantiﬁcation indicates that
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We then set out to demonstrate a physical interaction in vivo
between ASAP1 and Arf1 by co-immunoprecipitation. BHK
cells were transfected with the plasmid constructs encoding for
HA-Arf1 and FLAG-ASAP1. 24 h post-transfection, the cells
were exposed or not to AlFx, solubilized in the presence of the
cross-linker DTSSP, and then submitted to immunoprecipita-
tion with an anti-FLAG antibody coupled to agarose-beads.
As shown in Fig. 2, very low levels of Arf1 could be found co-
immunoprecipitated with ASAP1 in the absence of AlFx. How-
ever, the amount of Arf1 co-immunoprecipitated with ASAP1
was signiﬁcantly increased in the presence ofAlFx.As a negative
control cell lysates were immunoprecipitated with an irrelevant
antibody. In conclusion, cells exposed to AlFx sustain an
Arf1GDP-AlFx-ASAP1 complex. Together with our in vitro
experiments this result indicates that AlFx stabilizes eﬃciently
the interaction between Arf1GDP and ASAP1.
Since the inhibitory eﬀects of wild-type ASAP1 overexpres-
sion on the formation of FCs and cell spreading are well de-
scribed, the addition of AlFx could be functionally assessed.
FCs are typically enriched in paxillin that decorate the ends
of actin cables oriented towards the periphery of the cell. As
shown in Fig. 3A, when REF52 cells are plated on ﬁbronectin
they form FCs as early as 4 h, with fully mature FCs visible all
around the cells at 6 h accompanied with a progressive spread-
ing of the cells also achieved by 6 h. In cells overexpressing
FLAG-ASAP1, we observed that FCs were totally absent at
4 h and the presence of rounded cells. FCs could be detected
at 6 h and were mature only after 8 h in wellspread cells
(Fig. 3A). This is consistent with previous reports showing that
overexpression of ASAP1 delays but does not prevent the for-
mation of FCs. ASAP1 could either act solely by hydrolyzing
the GTP of Arf1 or act as well as an eﬀector of the activated
Arf1GTP. We reasoned that if ASAP1 were acting as an eﬀec-
tor for Arf1GTP, the stabilization by AlFx of a complex be-
tween ASAP1 and Arf1 in an active conformation shouldFig. 2. In vivo formation of a complex between Arf1 and ASAP1
stabilized by AlFx. BHK cells were transfected with plasmids encoding
for ASAP1-FLAG and HA-Arf1. 24 h post-transfection the cells were
exposed or not to AlFx for 30 min and after Tx-100 solubilization
submitted to immunoprecipitation with an irrelevant control antibody
or the anti-FLAG. After SDS–PAGE, the presence of Arf1 was
revealed by immunoblot and chemiluminescence. Ig LC indicates the
light chain of the immunoprecipitating antibody. Aliquots of total
lysates were also analyzed separately to determine the total amounts of
transfected FLAG-ASAP1 and HA-Arf1.
Fig. 3. The complex ASAP1-Arf1GDP-AlFx delays the recruitment of
paxillin within focal complexes. REF52 cells were transfected (ASAP1)
or not (Unt.) with the plasmid pSS45-ASAP1-FLAG. Sixteen hours
after transfection, the cells were trypsinized and replated on ﬁbronectin
for the indicated periods of time. After ﬁxation and permeabilization,
ASAP1-FLAG, polymerized actin and paxillin were stained using anti-
FLAG, phalloidin and anti-paxillin, respectively. Where indicated
AlFx was added to the medium the last two hours of the incubation
period. Samples were analyzed by confocal immunoﬂuorescence and
the mounted pictures are representative of at least three independent
experiments.lead to a greater delay in the formation of the FCs in cells
overexpressing ASAP1. In Fig. 3B, control or FLAG-ASAP1
transfected REF52 cells have been plated on coverslips coated
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AlFx alone had no obvious eﬀects on the formation of FCs
in control cells. Similarly, after 8 h incubation in normal media
ASAP1-transfected cells formed mature FCs and were well
spread, indicating that free ASAP1 does not aﬀect FCs forma-
tion under these conditions (Fig. 3A and B). However, in
ASAP1-transfected cells exposed to AlFx the FCs were virtu-
ally absent and the actin cytoskeleton was forming a net vertex
surrounding the cells with no apparent small ﬁlopodia oriented
outwards (Fig. 3B). Interestingly, when incubated for 12 h the
cells ultimately formed FCs. This delay is consistent with those
that others and we had observed in cells overexpressing wild-
type ASAP1 (see Fig. 3A). Thus, the ﬁnding that the appear-
ance of FCs is even further delayed is consistent with the role
hypothesized for AlFx stabilization of Arf1/ASAP1 in vivo.
Furthermore, since the GAP activity of ASAP1 is inoperative
within the complex, our results indicate that the GAP activity
of ASAP1 is not required for ASAP1 to interfere with FCs
formation.4. Discussion
AlFx activates the a subunit of heterotrimeric G proteins by
mimicking the c-phosphate of GTP upon its insertion, together
with GDP, within the nucleotide-binding pocket [9]. However,
following the same experimental conditions that led to Ga acti-
vation, AlFx was found inactive on Ha-ras, Rap1A, Rab1A,
Rab1B, Rab3B, Arf1 and Arf6 ([10] and our unpublished re-
sults). Thus, it was concluded that small GTP-binding proteins
were insensitive to AlFx, and as such AlFx could be used to
discriminate biological functions associated to either heterotri-
meric or small GTP-binding proteins. For this reason, even to-
day, in experimental models where Arf proteins are found to
be activated following AlFx treatment it is suggested that it
is an indirect eﬀect of the prior stimulation of an heterotrimeric
G-protein. However, almost 10 years ago AlFx was found to
stabilize a complex between RasGDP-AlFp120GAP allowing
for the crystallization of the complex [11,12]. Similar results
were reported for Cdc42 and RhoA suggesting that Arf pro-
teins could also be sensitive to AlFx in the presence of an
Arf-GAP [13,24].
Here, we show for the ﬁrst time that AlFx can stabilize a
complex between Arf1GDP and PZA, the minimal active
fragment of the Arf1-GAP ASAP1 [3]. We and others had pre-
viously shown that Arf1GDP is soluble while its active GTP-
bound form associates to lipid membranes [22,23]. We took
advantage of this property and performed sedimentation
experiments to monitor the association of myr-Arf1 to lipo-
somes. When myr-Arf1 and PZA proteins were mixed together
in the absence of AlFx their supernatant/pellet distributions
were unaﬀected. However, when AlFx was added to the reac-
tion, myr-Arf1 was translocated to the membrane indicating
that it had been converted to an active conformation resem-
bling that of an Arf1GTP. In addition, myr-Arf1 recruited
PZA onto the liposomes in a dose-dependent and saturable
manner. The quantitation demonstrates that the interaction
obeys to a stoichiometry of one molecule of Arf1 for one mol-
ecule of PZA. These studies indicate that AlFx mimics the
presence of the c-phosphate of the GTP in myr-Arf1GDP,
converting Arf1 in an active GTP-bound conformation that
interacts with PZA in association to lipid membranes.Our results help to explain the original data showing that
AlFx could stimulate b-COP recruitment to Golgi-membranes
in an Arf-dependent manner [25]. Furthermore, they are con-
sistent with two recent reports. First, AlFx was used to demon-
strate that a complex between the puriﬁed coatomer, including
the integral ArfGAP1, and Arf1GDP was possible solely onto
small synthetic liposomes of a given size due to the presence of
a curvature-sensing domain within ArfGAP1 [26]. Second, in
NRK cells, overexpressed ArfGAP1 was co-precipitated with
endogenous b-COP only after the cells were pretreated with
AlFx [27]. These results can easily be explained by the forma-
tion of a direct complex between Arf1 and ArfGAP1 stabilized
by AlFx as demonstrated for Arf1 and ASAP1 in our experi-
ments. Similarly to Ras and RhoA, one can envision to use
AlFx to co-crystallize Arf1 or Arf6 with their cognate GAPs
to obtain information regarding the molecular mechanism of
GTP hydrolysis.
Overexpression of ASAP1 has been shown to retard the
formation of FCs, cell spreading and cell motility in various
cell systems. Whereas in all cases the GAP activity appears to
be required to alter the cell motility, there are contradictory
results as to whether a delay in cell spreading and FCs for-
mation are dependent on the GAP activity. While the cata-
lytically inactive mutant, R497K, appeared much less
eﬀective than the wild-type ASAP1 to disturb FCs formation,
in contrast the ASAP1 mutant deleted of the entire GAP do-
main, DZA, inhibited cell spreading and FCs formation to a
much greater extent than the wild-type protein. It was pro-
posed that the point mutant R497K that can still bind
Arf1, in contrary to DZA, would act as a dominant negative
preventing Arf1 to bind to the eﬀector required to alter FCs
formation. However, this is in opposition with the inhibitory
results observed by overexpression of the wild-type protein
that could also act to sequester Arf1. Instead, we propose a
model whereby ASAP1 would simply act as an eﬀector of
Arf1GTP. The binding to Arf1GTP would result in a confor-
mational change of ASAP1 to reveal the eﬀector domain
responsible for the observed inhibitory eﬀects. Consistent
with this model, we propose that the GAP domain deleted
mutant DZA would always be in an opened conformation
with the eﬀector domain free to interact with its speciﬁc part-
ners. In contrast, the point mutation R497K would decrease
the aﬃnity of ASAP1 for Arf1GTP thereby reducing the
probability to adopt an opened conformation. In the presence
of AlFx, ASAP1 bound to Arf1 in an active conformation
(Arf1GDP-AlFx) would be blocked in an opened conforma-
tion revealing the eﬀector domain responsible for the inhibi-
tory eﬀects. Our model is in agreement with another study
suggesting that lipid binding to the PH domain of ASAP1
would cause a conformational change necessary to allow
for the binding of the substrate Arf1GTP [28]. Taken to-
gether, the results are consistent with our model whereby
ASAP1 acts as an eﬀector of Arf1GTP to interfere with
FCs formation and cell spreading. These eﬀector functions
are independent of the GAP catalytic activity per se, however
they are dependent on the formation of the Arf1GTP/GAP
complex and the multiple protein–protein interacting do-
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